Prevention of sporadic Alzheimer's disease: Lessons learned from clinical trials and future directions

The Lancet Neurology

Volumn 14, Issue 9, 2015, Pages 926-944

  Andrieu, Sandrine ^a,b,c   Coley, Nicola ^a,b,c   Lovestone, Simon ^d   Aisen, Paul S ^e   Vellas, Bruno ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; CYANOCOBALAMIN; FISH OIL; FLAVANOL DERIVATIVE; FLAVONOID; FOLIC ACID; GINKGO BILOBA EXTRACT; HOMOCYSTEINE; HORMONE; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; OMEGA 3 FATTY ACID; PYRIDOXINE; VITAMIN D;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); EXERCISE; FUTUROLOGY; HORMONE SUBSTITUTION; HUMAN; INTERVENTION STUDY; NEUROPROTECTION; PATIENT COUNSELING; PHYSICAL ACTIVITY; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAMIN SUPPLEMENTATION; FORECASTING; LEARNING; RISK FACTOR; RISK REDUCTION; TRENDS;

ALZHEIMER DISEASE; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; FORECASTING; HUMANS; LEARNING; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84939567406     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00153-2     Document Type: Review

References (144)

1. Wimo A, Jonsson L, Bond J, Prince M, Winblad B The worldwide economic impact of dementia 2010. Alzheimers Dement 2013, 9:1-11.e3.
2. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012, 78:1456-1463.
3. Lutz W, Sanderson W, Scherbov S The coming acceleration of global population ageing. Nature 2008, 451:716-719.
4. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013, 9:63-75.e2.
5. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007, 3:186-191.
6. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol 2014, 13:788-794.
7. Coley N, Andrieu S, Gardette V, et al. Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev 2008, 30:35-66.
8. Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med 2010, 153:176-181.
9. Ritchie K, Carriere I, Ritchie CW, Berr C, Artero S, Ancelin ML Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ 2010, 341:c3885.
10. Barnes DE, Yaffe K The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011, 10:819-828.
11. Cummings JL, Cole G Alzheimer disease. JAMA 2002, 287:2335-2338.
12. Feldman HH, Jacova C Primary prevention and delay of onset of AD/dementia. Can J Neurol Sci 2007, 34(suppl 1):S84-S89.
13. Peters KR, Lynn Beattie B, Feldman HH, Illes J A conceptual framework and ethics analysis for prevention trials of Alzheimer disease. Prog Neurobiol 2013, 110:114-123.
14. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med 2014, 6:228fs13.
15. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
16. Sperling RA, Jack CR, Aisen PS Testing the right target and right drug at the right stage. Sci Transl Med 2011, 3:111cm33.
17. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012, 11:669-678.
18. Yang L, Rieves D, Ganley C Brain amyloid imaging-FDA approval of florbetapir F18 injection. N Engl J Med 2012, 367:885-887.
19. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013, 9:e1-e16.
20. Querfurth HW, LaFerla FM Alzheimer's disease. N Engl J Med 2010, 362:329-344.
21. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
22. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003, 163:1069-1075.
23. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2947-2958.
24. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662.
25. Viswanathan A, Raj S, Greenberg SM, et al. Plasma Aβ, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 2009, 72:268-272.
26. Ball K, Berch DB, Helmers KF, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 2002, 288:2271-2281.
27. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005, 30:1204-1215.
28. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005, 352:2379-2388.
29. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007, 6:501-512.
30. Oken BS, Zajdel D, Kishiyama S, et al. Randomized, controlled, six-month trial of yoga in healthy seniors: effects on cognition and quality of life. Altern Ther Health Med 2006, 12:40-47.
31. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004, 63:651-657.
32. Ford AH, Flicker L, Alfonso H, et al. Vitamins B(12), B(6), and folic acid for cognition in older men. Neurology 2010, 75:1540-1547.
33. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008, 300:2253-2262.
34. Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology 2009, 34:1065-1074.
35. Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68:1800-1808.
36. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008, 7:683-689.
37. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008, 70:2024-2035.
38. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012, 11:851-859.
39. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006, 354:2764-2772.
40. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009, 72:1555-1561.
41. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011, 10:969-977.
42. Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 2006, 84:361-370.
43. Muscari A, Giannoni C, Pierpaoli L, et al. Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: a randomized controlled trial. Int J Geriatr Psychiatry 2010, 25:1055-1064.
44. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008, 300:1027-1037.
45. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010, 5:e12244.
46. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008, 71:430-438.
47. Yurko-Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010, 6:456-464.
48. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 2010, 91:1725-1732.
49. Smith GE, Housen P, Yaffe K, et al. A cognitive training program based on principles of brain plasticity: results from the Improvement in Memory with Plasticity-based Adaptive Cognitive Training (IMPACT) study. J Am Geriatr Soc 2009, 57:594-603.
50. Klusmann V, Evers A, Schwarzer R, et al. Complex mental and physical activity in older women and cognitive performance: a 6-month randomized controlled trial. J Gerontol A Biol Sci Med Sci 2010, 65:680-688.
51. Kwok TC, Lam LC, Sea MM, Goggins W, Woo J A randomized controlled trial of dietetic interventions to prevent cognitive decline in old age hostel residents. Eur J Clin Nutr 2012, 66:1135-1140.
52. Mastroiacovo D, Kwik-Uribe C, Grassi D, et al. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study-a randomized controlled trial. Am J Clin Nutr 2015, 101:538-548.
53. Desideri G, Kwik-Uribe C, Grassi D, et al. Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. Hypertension 2012, 60:794-801.
54. Liu-Ambrose T, Nagamatsu LS, Graf P, Beattie BL, Ashe MC, Handy TC Resistance training and executive functions: a 12-month randomized controlled trial. Arch Intern Med 2010, 170:170-178.
55. Ihle-Hansen H, Thommessen B, Fagerland MW, et al. Multifactorial vascular risk factor intervention to prevent cognitive impairment after stroke and TIA: a 12-month randomized controlled trial. Int J Stroke 2014, 9:932-938.
56. Vidovich MR, Lautenschlager NT, Flicker L, Clare L, McCaul K, Almeida OP The PACE study: a randomized clinical trial of cognitive activity strategy training for older people with mild cognitive impairment. Am J Geriatr Psychiatry 2015, 23:360-372.
57. Anderson-Hanley C, Arciero PJ, Brickman AM, et al. Exergaming and older adult cognition: a cluster randomized clinical trial. Am J Prev Med 2012, 42:109-119.
58. Hajjar I, Hart M, Chen YL, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med 2012, 172:442-444.
59. Barnes DE, Santos-Modesitt W, Poelke G, et al. The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults. JAMA Intern Med 2013, 173:797-804.
60. Lee KS, Lee Y, Back JH, et al. Effects of a multidomain lifestyle modification on cognitive function in older adults: an eighteen-month community-based cluster randomized controlled trial. Psychother Psychosom 2014, 83:270-278.
61. Diamond K, Mowszowski L, Cockayne N, et al. Randomized controlled trial of a healthy brain ageing cognitive training program: effects on memory, mood, and sleep. J Alzheimers Dis 2015, 44:1181-1191.
62. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015, 385:2255-2263.
63. Wolinsky FD, Vander Weg MW, Howren MB, Jones MP, Dotson MM A randomized controlled trial of cognitive training using a visual speed of processing intervention in middle aged and older adults. PLoS One 2013, 8:e61624.
64. Kwok T, Wong A, Chan G, et al. Effectiveness of cognitive training for Chinese elderly in Hong Kong. Clin Interv Aging 2013, 8:213-219.
65. Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One 2013, 8:e61483.
66. Gomez-Isla T, Blesa R, Boada M, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord 2008, 22:21-29.
67. Peters O, Lorenz D, Fesche A, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging 2012, 16:544-548.
68. Makizako H, Doi T, Shimada H, et al. Does a multicomponent exercise program improve dual-task performance in amnestic mild cognitive impairment? A randomized controlled trial. Aging Clin Exp Res 2012, 24:640-646.
69. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010, 9:702-716.
70. Hardy J, Bogdanovic N, Winblad B, et al. Pathways to Alzheimer's disease. J Intern Med 2014, 275:296-303.
71. Cummings JL, Doody R, Clark C Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69:1622-1634.
72. Callaway E Alzheimer's drugs take a new tack. Nature 2012, 489:13-14.
73. Danthiir V, Burns NR, Nettelbeck T, Wilson C, Wittert G The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older adults. Nutr J 2011, 10:117.
74. Richard E, Van den Heuvel E, Moll van Charante EP, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord 2009, 23:198-204.
75. Wharton W, Gleason CE, Miller VM, Asthana S Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog). Brain Res 2013, 1514:12-17.
76. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 2013, 36:555-564. ASPREE Investigator Group.
77. Sink KM, Espeland MA, Rushing J, et al. The LIFE Cognition Study: design and baseline characteristics. Clin Interv Aging 2014, 9:1425-1436.
78. Cyarto EV, Lautenschlager NT, Desmond PM, et al. Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trial. BMC Psychiatry 2012, 12:167.
79. Vellas B, Carrie I, Gillette-Guyonnet S, et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. J Prev Alzheimers Dis 2014, 1:13-22.
80. Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014, 11:532-546.
81. Crenshaw DG, Gottschalk WK, Lutz MW, et al. Using genetics to enable studies on the prevention of Alzheimer's disease. Clin Pharmacol Ther 2013, 93:177-185.
82. Birks J Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, 1. CD005593.
83. Qiu C, Winblad B, Fratiglioni L The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005, 4:487-499.
84. Ashby EL, Kehoe PG Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Opin Investig Drugs 2013, 22:1229-1242.
85. Goodison WV, Frisardi V, Kehoe PG Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome. J Alzheimers Dis 2012, 30(suppl 2):S269-S282.
86. Birge SJ The role of estrogen in the treatment and prevention of dementia: introduction. Am J Med 1997, 103:1S-2S.
87. Carroll JC, Rosario ER The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease. Curr Alzheimer Res 2012, 9:18-34.
88. Craig MC, Murphy DG Estrogen therapy and Alzheimer's dementia. Ann N Y Acad Sci 2010, 1205:245-253.
89. Sherwin BB Estrogen therapy: is time of initiation critical for neuroprotection?. Nat Rev Endocrinol 2009, 5:620-627.
90. Jaturapatporn D, Isaac MG, McCleery J, Tabet N Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012, 2. CD006378.
91. Imbimbo BP, Solfrizzi V, Panza F Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?. Front Aging Neurosci 2010, 2:19.
92. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011, 7:402-411.
93. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001, 345:1515-1521.
94. Cole GM, Frautschy SA Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets 2010, 9:140-148.
95. Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. Biochem Biophys Res Commun 1994, 201:748-755.
96. Pietri S, Maurelli E, Drieu K, Culcasi M Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997, 29:733-742.
97. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002, 99:12197-12202.
98. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5:64-74.
99. Yang Y, Song W Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience 2013, 250:140-150.
100. Moreira PI Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis 2012, 30(suppl 2):S199-S215.
101. Searcy JL, Phelps JT, Pancani T, et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis 2012, 30:943-961.
102. Kandiah N, Feldman HH Therapeutic potential of statins in Alzheimer's disease. J Neurol Sci 2009, 283:230-234.
103. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 2002, 22:1752-1762.
104. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005, 82:806-812. Homocysteine Lowering Trialists' Collaboration.
105. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 2012, 27:592-600.
106. Markesbery WR, Carney JM Oxidative alterations in Alzheimer's disease. Brain Pathol 1999, 9:133-146.
107. Kryscio RJ, Abner EL, Schmitt FA, et al. A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. J Nutr Health Aging 2013, 17:72-75.
108. Uauy R, Dangour AD Nutrition in brain development and aging: role of essential fatty acids. Nutr Rev 2006, 64:S24-S33.
109. Williams RJ, Spencer JP Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med 2012, 52:35-45.
110. Etgen T, Sander D, Bickel H, Sander K, Forstl H Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dement Geriatr Cogn Disord 2012, 33:297-305.
111. Durk MR, Han K, Chow EC, et al. 1α,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer's disease. J Neurosci 2014, 34:7091-7101.
112. Scarmeas N, Stern Y Cognitive reserve: implications for diagnosis and prevention of Alzheimer's disease. Curr Neurol Neurosci Rep 2004, 4:374-380.
113. Willis SL, Tennstedt SL, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 2006, 296:2805-2814.
114. Voss MW, Nagamatsu LS, Liu-Ambrose T, Kramer AF Exercise, brain, and cognition across the life span. J Appl Physiol (1985) 2011, 111:1505-1513.
115. Phillips C, Baktir MA, Srivatsan M, Salehi A Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Front Cell Neurosci 2014, 8:170.
116. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009, 302:627-637.
117. Kozauer N, Katz R Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 2013, 368:1169-1171.
118. Vellas B, Aisen PS, Sampaio C, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 2011, 95:594-600.
119. Mathews M, Abner E, Caban-Holt A, Kryscio R, Schmitt F CERAD practice effects and attrition bias in a dementia prevention trial. Int Psychogeriatr 2013, 25:1115-1123.
120. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014, 71:961-970.
121. Langbaum JB, Hendrix SB, Ayutyanont N, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement 2014, 10:666-674.
122. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009, 86:97-100.
123. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009, 66:1447-1455.
124. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
125. Hampel H, Wilcock G, Andrieu S, et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 2011, 95:579-593.
126. Cook CN, Murray ME, Petrucelli L Understanding biomarkers of neurodegeneration: novel approaches to detecting tau pathology. Nat Med 2015, 21:219-220.
127. Meinert CL, Breitner JC Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 2008, 4(1 suppl 1):S7-S14.
128. Dangour AD, Allen E, Richards M, Whitehouse P, Uauy R Design considerations in long-term intervention studies for the prevention of cognitive decline or dementia. Nutr Rev 2010, 68(suppl 1):S16-S21.
129. Amieva H, Jacqmin-Gadda H, Orgogozo JM, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005, 128(pt 5):1093-1101.
130. Leoutsakos JM, Bartlett AL, Forrester SN, Lyketsos CG Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example. Alzheimers Dement 2014, 10:152-161.
131. Gares V, Andrieu S, Dupuy JF, Savy N A comparison of the constant piecewise weighted logrank and Fleming-Harrington tests. Electron J Stat 2014, 8:841-860.
132. Gares V, Andrieu S, Dupuy JF, Savy N An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials. Stat Med 2014, 34:541-557.
133. Coley N, Gardette V, Cantet C, et al. How should we deal with missing data in clinical trials involving Alzheimer's disease patients?. Curr Alzheimer Res 2011, 8:421-433.
134. Stephenson D, Perry D, Bens C, et al. Charting a path toward combination therapy for Alzheimer's disease. Expert Rev Neurother 2015, 15:107-113.
135. Weiner MW, Aisen PS, Jack CR, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010, 6:202. 11.e7.
136. Dehnel T The European Dementia Prevention Initiative. Lancet Neurol 2013, 12:227-228.
137. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
138. Mangialasche F, Kivipelto M, Solomon A, Fratiglioni L Dementia prevention: current epidemiological evidence and future perspective. Alzheimers Res Ther 2012, 4:6.
139. Kryscio RJ, Mendiondo MS, Schmitt FA, Markesbery WR Designing a large prevention trial: statistical issues. Stat Med 2004, 23:285-296.
140. Stough CK, Pase MP, Cropley V, et al. A randomized controlled trial investigating the effect of Pycnogenol and Bacopa CDRI08 herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: the Australian Research Council Longevity Intervention (ARCLI) study protocol (ANZCTR12611000487910). Nutr J 2012, 11:11.
141. Boss HM, Van Schaik SM, Deijle IA, et al. A randomised controlled trial of aerobic exercise after transient ischaemic attack or minor stroke to prevent cognitive decline: the MoveIT study protocol. BMJ Open 2014, 4:e007065.
142. Brainin M, Matz K, Nemec M, et al. Prevention of poststroke cognitive decline: ASPIS - a multicenter, randomized, observer-blind, parallel group clinical trial to evaluate multiple lifestyle interventions - study design and baseline characteristics. Int J Stroke 2013, published online Nov 10. 10.1111/ijs.12188.
143. Wang P, Wang Y, Feng T, et al. Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE). BMC Neurol 2012, 12:88.
144. Rovner BW, Casten RJ, Hegel MT, Leiby BE Preventing cognitive decline in older African Americans with mild cognitive impairment: design and methods of a randomized clinical trial. Contemp Clin Trials 2012, 33:712-720.